Workflow
Business spin - off
icon
Search documents
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Seeking Alphaยท 2025-05-26 03:24
Group 1 - The core viewpoint is that Medtronic's decision to spin off its diabetes business is expected to act as a near-term catalyst for its stock price [1] - A 'Buy' rating was assigned to Medtronic in March 2025, emphasizing the strength in its cardiac ablation solutions [1] - The company has a beneficial long position in its shares, indicating confidence in its future performance [1]